Cargando…
A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Compuscript
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832958/ https://www.ncbi.nlm.nih.gov/pubmed/34708999 http://dx.doi.org/10.20892/j.issn.2095-3941.2021.0520 |
_version_ | 1784648821821669376 |
---|---|
author | Guo, Yuchen Zhou, Yangyang Qin, Wenxin |
author_facet | Guo, Yuchen Zhou, Yangyang Qin, Wenxin |
author_sort | Guo, Yuchen |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-8832958 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Compuscript |
record_format | MEDLINE/PubMed |
spelling | pubmed-88329582022-03-01 A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer Guo, Yuchen Zhou, Yangyang Qin, Wenxin Cancer Biol Med Editorial Compuscript 2022-02-15 2021-10-28 /pmc/articles/PMC8832958/ /pubmed/34708999 http://dx.doi.org/10.20892/j.issn.2095-3941.2021.0520 Text en Copyright: © 2022, Cancer Biology & Medicine https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0 (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Editorial Guo, Yuchen Zhou, Yangyang Qin, Wenxin A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer |
title | A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer |
title_full | A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer |
title_fullStr | A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer |
title_full_unstemmed | A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer |
title_short | A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer |
title_sort | crispr-cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832958/ https://www.ncbi.nlm.nih.gov/pubmed/34708999 http://dx.doi.org/10.20892/j.issn.2095-3941.2021.0520 |
work_keys_str_mv | AT guoyuchen acrisprcas9screenshowsthecombinationefficacyoflenvatinibplusepidermalgrowthfactorreceptorinhibitorsfortreatmentoflivercancer AT zhouyangyang acrisprcas9screenshowsthecombinationefficacyoflenvatinibplusepidermalgrowthfactorreceptorinhibitorsfortreatmentoflivercancer AT qinwenxin acrisprcas9screenshowsthecombinationefficacyoflenvatinibplusepidermalgrowthfactorreceptorinhibitorsfortreatmentoflivercancer AT guoyuchen crisprcas9screenshowsthecombinationefficacyoflenvatinibplusepidermalgrowthfactorreceptorinhibitorsfortreatmentoflivercancer AT zhouyangyang crisprcas9screenshowsthecombinationefficacyoflenvatinibplusepidermalgrowthfactorreceptorinhibitorsfortreatmentoflivercancer AT qinwenxin crisprcas9screenshowsthecombinationefficacyoflenvatinibplusepidermalgrowthfactorreceptorinhibitorsfortreatmentoflivercancer |